Abstract Details

Title BDNF as a surrogate biomarker for systemic chronic damage in lupus.

Topic Autoimmune Neurology

Presentation(s) P1 - Poster Session 1 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-033

Objective To investigate associations between clinical manifestations and brain-derived neurotrophic factor (BDNF) in patients with systemic lupus erythematosus (SLE).

Background The BDNF is a neurotrophin involved in memory, synaptic plasticity and neuronal survival, produced by neurons, endothelial cells, and lymphocytes. Studies suggested that BDNF is decreased in major depression and neurodegenerative diseases. In SLE, the BDNF correlated with the neuropsychiatric manifestation severity and organic brain changes.

Design/Methods We determined the BDNF levels (ELISA, RayBiotech) of 111 patients (48 with major neuropsychiatric manifestations, NPSLE) and 57 controls (CG). Epidemiological data, medication use, autoantibodies profile, the chronic damage index (SDI) and the disease activity index scores were collected. The SDI comprises 12 organ systems and evaluates non-reversible changes. All patients underwent neuropsychological assessment and anxiety and depression questionnaires were applied.

Results Most common neuropsychiatric manifestations were psychosis (13.5%), seizures (11.7%), polyneuropathy (8.1%), acute confusional state (7.2%) and cerebrovascular disease (7.2%). BDNF levels were significantly lower in SLE patients (CG 1,345.3 ng/ml ± 438.5; non-NPSLE 800.4 ± 502.7; NPSLE 779.7 ± 426.3; p<0.001). SDI (p=0.001), hypertension (p=0.003), and secondary antiphospholipid syndrome (p=0.039) were independently associated with lower BDNF, but not cognitive dysfunction.

Conclusions

The BDNF level is reduced in SLE patients independent of neuropsychiatric manifestation. BDNF was associated with higher SDI scores, hypertension, and antiphospholipid syndrome, suggesting that BDNF may be a marker for systemic chronic damage and reduced neuroprotective function.

Authors/Disclosures
Helena Alessi (UNIFESP/EPM) PRESENTER	No disclosure on file
Livia A. Dutra, MD (Hospital Israelita Albert Einstein)	Dr. Dutra has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyverna. The institution of Dr. Dutra has received research support from Hospital Israelita Albert Einstein. The institution of Dr. Dutra has received research support from Laboratório Fleury. Dr. Dutra has received personal compensation in the range of $0-$499 for serving as a Speaker with Roche.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Fabiano F. Abrantes, MD (Medvital)	Dr. Abrantes has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Orlando G. Barsottini, MD, PhD (Universidade Federal de São Paulo)	Dr. Barsottini has nothing to disclose.

��ɫ��

��ɫ��